ECLAT Health Solutions Completes Management Buyout From Gulf Capital, Opening Next Chapter of Growth

Key Takeaways

• 10x revenue and EBITDA growth achieved in five years.
• Workforce expanded from 450 to over 4,000 employees globally.
• Proprietary AI platform evaire powers end‑to‑end coding and analytics.
• Management buyout returns full ownership to founders and leadership.
• Gulf Capital exits after deploying over $3 billion across funds.

Pulse Analysis

The management buyout of ECLAT Health Solutions reflects a broader trend of private‑equity‑backed healthcare tech firms reaching maturity and opting for founder‑led ownership. Over the past five years, Gulf Capital’s capital and operational expertise helped ECLAT scale its revenue cycle management (RCM) and risk‑adjustment services, driving a 75% compound annual EBITDA growth rate. By returning to founder control, ECLAT can now align its long‑term product roadmap—centered on the evaire AI platform—with client needs without external governance constraints, accelerating innovation cycles and pricing power.

ECLAT operates in a highly competitive RCM market where AI and analytics are becoming differentiators. The evaire platform combines agentic AI with deep payer expertise to automate chart retrieval, coding, and confidence scoring, reducing manual effort and improving claim accuracy. As hospitals and health systems grapple with rising administrative costs and tighter reimbursement models, solutions that deliver measurable efficiency gains are in high demand. ECLAT’s expanded global talent pool—spanning the United States, India and the Philippines—provides a cost‑effective delivery model that can scale quickly to meet the growing volume of payer‑centric services.

For Gulf Capital, the exit underscores the firm’s Control Growth Buyout model, which seeks to acquire majority stakes, drive operational improvements, and exit at peak valuation. Deploying over $3 billion across 44 investments, the firm’s success with ECLAT may attract additional capital to similar healthcare technology opportunities. The MBO also signals to the market that mature, AI‑enabled RCM providers can thrive under founder leadership, potentially prompting more buy‑outs or strategic partnerships as the sector consolidates around technology‑driven efficiency solutions.